KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 76 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,678,721 | +40.1% | 174,322 | +30.9% | 0.00% | +33.3% |
| Q2 2023 | $1,198,098 | +53.0% | 133,122 | +33.6% | 0.00% | +50.0% |
| Q1 2023 | $783,029 | +3.3% | 99,622 | -11.1% | 0.00% | 0.0% |
| Q4 2022 | $757,945 | -54.4% | 112,122 | -2.2% | 0.00% | -60.0% |
| Q3 2022 | $1,663,000 | +36.8% | 114,622 | -7.3% | 0.01% | +66.7% |
| Q2 2022 | $1,216,000 | +48.1% | 123,622 | +121.9% | 0.00% | +50.0% |
| Q1 2022 | $821,000 | -46.1% | 55,722 | -51.6% | 0.00% | -50.0% |
| Q4 2021 | $1,523,000 | -27.5% | 115,122 | -4.4% | 0.00% | -20.0% |
| Q3 2021 | $2,101,000 | +373.2% | 120,422 | +550.2% | 0.01% | +400.0% |
| Q2 2021 | $444,000 | +81.2% | 18,522 | +94.5% | 0.00% | 0.0% |
| Q1 2021 | $245,000 | +8.4% | 9,522 | -6.8% | 0.00% | 0.0% |
| Q2 2019 | $226,000 | – | 10,222 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 589,270 | $8,686,000 | 5.61% |
| GREAT POINT PARTNERS LLC | 874,197 | $12,886,000 | 3.11% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 383,233 | $10,805,000 | 2.44% |
| Frazier Life Sciences Management, L.P. | 1,572,192 | $23,174,000 | 1.98% |
| TANG CAPITAL MANAGEMENT LLC | 648,269 | $9,555,000 | 1.91% |
| Deep Track Capital, LP | 1,729,757 | $25,497,000 | 1.64% |
| Vivo Capital, LLC | 1,533,559 | $22,605,000 | 1.56% |
| Monashee Investment Management LLC | 264,111 | $3,893,000 | 1.13% |
| COMMODORE CAPITAL LP | 312,553 | $4,607,000 | 1.03% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,746,300 | $25,740,000 | 0.79% |